Sumatriptan

Early intrauterine death (< 22 weeks)

id	Study   Auto Yusuf (Control exposed to Naratriptan), 2018Ephross (Control exposed to Naratriptan), 2014O'Quinn, 1999Shuhaiber (Control exposed to other treatments), 1998Shuhaiber (Control unexposed, disease free), 1998	Lib. in paper	Exposition period  Auto during pregnancy (anytime or not specified)1st trimester2nd trimester3rd trimester2nd and/or 3rd trimesterthroughout pregnancyearly pregnancydays before deliverylate pregnancypreconception-onlypericonceptionalpreconceptional for kinetic reasonat least 1st trimester3 months (or more) before pregnancy or during pregnancy1st and 2nd trimester3 months or more before pregnancy or1st trimester	Study type  All studies Case control excluded Only case control	Control type    Auto unexposed (general population or NOS)unexposed, sickunexposed, disease freeexposed to other treatment, sicknot specifiedwhatever (meta-analysis)	Tags	OR 95%CI	x1/n1 x0/n0	no cases	no exposed	ROB	Ref.
S3552 R7055	Yusuf (Control exposed to Naratriptan), 2018	Spontaneous abortion (NOS)	1st trimester	retrospective cohort (claims database)	exposed to other treatment, sick	Adjustment: No	1.04 [0.71;1.53] C	629/3,496   33/190	662	3,496		ref
S3488 R6722	Ephross (Control exposed to Naratriptan), 2014	Spontaneous loss (<20 weeks of gestation)	1st trimester	prospective cohort	exposed to other treatment, sick	Adjustment: No	0.65 [0.24;1.73] C	34/528   5/52	39	528		ref
S3532 R6979	O'Quinn, 1999	Spontaneous abortion (NOS)	1st trimester	prospective cohort	unexposed, sick	Adjustment: No	0.87 [0.33;2.28] C	8/76   11/92	19	76		ref
S3490 R6734	Shuhaiber (Control exposed to other treatments), 1998	Spontaneous abortions, miscarriages (NOS)	during pregnancy (anytime or not specified)	prospective cohort	exposed to other treatment, sick excluded	Adjustment: No	1.94 [0.69;5.48] C excluded (control group)	11/96   6/96	17	96		ref
S3491 R6738	Shuhaiber (Control unexposed, disease free), 1998	Spontaneous abortions, miscarriages (NOS)	during pregnancy (anytime or not specified)	prospective cohort	unexposed, disease free	Adjustment: No	2.98 [0.91;9.70] C	11/96   4/96	15	96		ref
					Total	4 studies	1.06 [0.68;1.67]		735	4,196
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

Sensitivity analysis

Publication bias and p-hacking diagnosis

Sub-groups analysis using all included studies

excluded 3490